Finanzen von ALX Oncology Holdings Inc (ALXO)ALXOALX Oncology Holdings Inc

Evaluating the bottom line, ALX Oncology Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -80.65%, provide a clear picture of how effectively ALXO converts its operational activities into shareholder value.

In the context of the broader market, ALXO competes directly with industry leaders such as VRXA and IVVD. With a market capitalization of $158.33M, it holds a significant position in the sector. When comparing efficiency, ALXO's gross margin of N/A stands against VRXA's N/A and IVVD's 91.09%. Such benchmarking helps identify whether ALX Oncology Holdings Inc is trading at a premium or discount relative to its financial performance.

ALX Oncology has faced significant net income losses, with the latest reported loss of $17.9 million in Q1 2026. Despite this, the company has maintained a strong current ratio of 9.71, indicating good liquidity.